Workflow
VCI Global Powers Food Security Technology Company Agroz (AGRZ) to Nasdaq: Successful IPO Pricing and Trading Begins Today
Globenewswire· 2025-10-01 12:08
VCIG Strengthens Leadership in Cross-Border Capital Markets with Over US$23 Million Raised for Clients and US$20 Million in Advisory Fees GeneratedKUALA LUMPUR, Malaysia, Oct. 01, 2025 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”), through its capital advisory arm, V Capital Consulting Group Limited (“VCCG”), today announced the successful Nasdaq listing of Agroz Inc. (NASDAQ:AGRZ) (“Agroz”), an agricultural technology company advancing food security technology, with ...
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing
Globenewswire· 2025-10-01 12:05
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3% royalty on future net sales of dotinurad MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains an ...
Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer
Prnewswire· 2025-10-01 12:05
Accessibility StatementSkip Navigation SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker testing to help deliver information to doctors and patients, today announced the appointment of Tiffany Inglis, MD, FACOG, as Chief Medical Officer. With extensive clinical leadership expertise, Dr. Inglis will lead Sera's clinical operations to establish the company as ...
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
Globenewswire· 2025-10-01 12:03
CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and difficult-to-treat diseases, today announced that its Board of Directors has authorized a new share repurchase program to repurchase up to $200 million of shares of Catalyst's outstanding common stock between October 1, 2025, and Decemb ...
Bitcoin Depot Reports Strong Preliminary Third Quarter 2025 Financial Results
Globenewswire· 2025-10-01 12:00
ATLANTA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bitcoin Depot Inc. (Nasdaq: BTM) (“Bitcoin Depot” or the “Company”), a U.S.-based Bitcoin ATM operator and leading fintech company, today announced certain preliminary financial results for the third quarter ended September 30, 2025. The Company expects revenue for the third quarter of 2025 to be approximately $160 million, representing an 18% increase compared to the $135.3 million reported in the third quarter of 2024. The Company also expects to report an approx ...
SLR Investment Corp. Schedules the Release of its Financial Results for the Quarter Ended September 30, 2025
Globenewswire· 2025-10-01 12:00
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- SLR Investment Corp. (the “Company”) (NASDAQ: SLRC) today announced that it will release its financial results for the quarter ended September 30, 2025 on Tuesday, November 4, 2025 after the close of the financial markets. The Company will host an earnings conference call and audio webcast at 10:00 a.m. (Eastern Time) on Wednesday, November 5, 2025. All interested parties may participate in the conference call by dialing (800) 245-3047 approximately 5-10 minutes p ...
Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update
Globenewswire· 2025-10-01 12:00
Inspira delivered major milestones throughout and following the six months ended June 30, 2025, including the receipt of $49.5 million in binding purchase orders, clinical validation in leading hospitals, 97.35% accuracy for its HYLA blood sensor, and strategic patent protection, underscoring accelerating commercial momentum.RA'ANANA, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”), a pioneer in innovative life-support and di ...
Parex Resources Announces Production Update and Timing of Q3 2025 Results
Globenewswire· 2025-10-01 12:00
CALGARY, Alberta, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT) announces a production update and expects to release its Q3 2025 financial and operating results on November 4, 2025. Q3 2025 Production Update(1)(2) Estimated Q3 2025 average production was 44,000 boe/d, with production in the quarter supported by strong base asset performance, growth at LLA-32, and positive exploration results, offset by lower production at Capachos. The prior quarter’s (Q2 2025) ...
GrowGeneration to Participate in IgniteIt Cannabis Market Spotlight on October 8, 2025
Globenewswire· 2025-10-01 12:00
DENVER, Oct. 01, 2025 (GLOBE NEWSWIRE) -- GrowGeneration Corp. (NASDAQ: GRWG) (“GrowGen” or the “Company”), the nation’s largest specialty hydroponic and organic gardening retailer, today announced that members of management will participate in the IgniteIt “Cannabis Market Spotlight: California” event, which is being held October 8, 2025 in Anaheim, California. Jason Holland, GrowGen’s Vice President of Product Innovation & Commercial Solutions, will participate in a panel discussion titled “Efficiency Equ ...
Solid Biosciences to Present at Upcoming Scientific Meetings
Globenewswire· 2025-10-01 12:00
CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from its neuromuscular and cardiac programs at the World Muscle Society (WMS) 2025 Annual International Congress, October 7-11, 2025, in Vienna, Austria, and at the European Society of Gene & Cell Therapy (ESGCT) 2025 Annual Congress, October 7-12, 2025, in Seville, Spain. “Our presentations at WM ...